Dr. Lal Path Labs Ltd. (LALPATHLAB) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 19, 2026 3 min read

Dr. Lal Path Labs enters the new fiscal year facing questions on whether its Q4 growth momentum can withstand the seasonal lull typical of the June quarter. Investors will be closely watching for signs of margin stabilization within the company's guided 27-28% range as it balances aggressive network expansion with rising channel-partner costs.

Quick Details

Results date	July 24, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 702.7 Cr
Previous quarter PAT	Rs. 131.3 Cr
Market cap	Rs. 28,287.2 Cr
CMP	Rs. 1687.4

Dr. Lal Path Labs Ltd. Q1 Results Date and Time

The board of directors is scheduled to meet on July 24, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.

What to expect from Dr. Lal Path Labs Ltd.'s Q1 FY27 results

Dr. Lal Path Labs is expected to show revenue growth exceeding its FY26 full-year run-rate of 12%, building on the 16.6% YoY growth recorded in Q4 FY26. While Q1 is seasonally the weakest period for diagnostic volumes, the company benefits from a low base of 11.3% growth in the year-ago quarter. EBITDA margins are expected to land within the management-guided range of 27-28%, which represents a significant YoY compression from the 32.9% margin reported in Q1 FY26. Operating expenses, particularly franchisee and collection-centre fees, are expected to remain elevated as a percentage of revenue following the addition of 600-800 collection centres during FY26. Management's commentary on the realization per test and the impact of monsoon-related acute test volumes will be the primary focus for the upcoming results call.

Key Things To Watch

Network expansion and channel costs: Monitoring the impact of recent network additions on operating leverage.

Impact of 600-800 new collection centres added in FY26 on current quarter throughput
Trajectory of channel-partner fees following the 41.2% YoY increase observed in Q4 FY26

Operational and demand metrics: Tracking volume trends and price-mix dynamics.

YoY change in non-COVID test counts with a focus on acute versus preventive mix
Price-mix impact on realization per test given the absence of GST rate changes

Cost structure stability: Assessing input cost pressures for the quarter.

Cost of materials ratio expected to remain in the 19-19.5% band
Absence of import duty changes on diagnostic reagents during Q1 FY27

Frequently Asked Questions

How did Dr. Lal Path Labs' revenue perform in the previous quarter?

Revenue from operations reached Rs. 702.7 Cr in Q4 FY26, representing a 16.6% YoY growth. This was the strongest growth performance in the FY26 sequence.

What is the management's guidance for EBITDA margins in FY27?

Management has guided for an EBITDA margin in the 27-28% range for FY27. This follows a margin of 26.6% in Q4 FY26 and 28.32% for the full FY26 year.

Did the company's cost of materials change during the quarter?

The cost of materials consumed remained steady at 19.2% of revenue in Q4 FY26, consistent with the Q1 FY26 level. No changes in customs duty on reagents were enacted during Q1 FY27 to alter this cost profile.